ImCheck obtient 20,18 millions d’euros de financement public dans le cadre du plan France 2030
29 août 2024 05h00 HE
|
ImCheck Therapeutics SAS
ImCheck reçoit un financement non-dilutif significatif afin d’accélérer l’avancement de deux programmes innovants, dans le traitement des cancer et des maladies infectieuses, en ligne avec l’ambition...
ImCheck Awarded EUR 20.18 Million from the French Government Through the France 2030 Investment and Innovation Plan
29 août 2024 05h00 HE
|
ImCheck Therapeutics SAS
FOR IMMEDIATE RELEASE -- ImCheck secures substantial non-dilutive funding to accelerate the progress of two breakthrough programs in cancer and infectious diseases, in support of France's 2030...
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
28 août 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced results from the INTEGUMENT-OLE long-term open-label study of once-daily roflumilast cream 0.05%.
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections
28 août 2024 07h00 HE
|
Revive Therapeutics Ltd.
TORONTO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers
21 août 2024 08h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients,...
PharmaTher’s Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)
19 août 2024 08h00 HE
|
PharmaTher Holdings Ltd.
TORONTO, Aug. 19, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announced today Sairiyo...
Multiple Myeloma Research Foundation (MMRF) Announces New Publication on CoMMpass℠ Study in Nature Genetics Defining Distinct Subtypes of Multiple Myeloma and High-Risk Genetic Markers
19 août 2024 05h05 HE
|
Multiple Myeloma Research Foundation
This MMRF-led collaborative initiative is the largest single sequencing study of multiple myeloma patients to dateCoMMpass findings provide an unprecedented, clearer definition of patients at highest...
AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update
16 août 2024 07h00 HE
|
AIM ImmunoTech Inc.
– Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications – Company to host conference call and webcast today, August...
Groundbreaking Crnic Institute Study Discovers Differences in Oxygen Physiology in People with Down Syndrome
15 août 2024 13h38 HE
|
Global Down Syndrome Foundation
Denver, Aug. 15, 2024 (GLOBE NEWSWIRE) -- The Global Down Syndrome Foundation (GLOBAL) is proud to support a groundbreaking new study published in Cell Reports by researchers from its partner and...
DiagnaMed Offering its Brain Health AI Platform for Investigating Weight Loss Drugs, such as Semaglutide (GLP-1), on Brain Function
15 août 2024 08h00 HE
|
DiagnaMed Holdings Corp.
TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, is...